Julie Prigent is a Project leader R&D – Principal Scientist at BIOMUNEX. Prior to joining the company, she worked at H-Immune and HiFiBio therapeutics (Paris, FR) in identifying targets of interest in Immuno-oncology field. Further, she was involved in developing therapeutic antibodies, from discovery to CMC, focused on targeting Tregs to restore anti-tumor immunity. She has a strong immunology and antibody engineering background acquired during her PhD at CEA (Saclay, FR) and Post-doctoral fellowship at the Pasteur Institute (Paris, FR). Here she worked on identifying therapeutic antibodies against toxins in the context of the fight against Bioterrorism and at studying the evolution of BnAbs in HIV patients. She is 1^st author in several articles in scientific journals but also co-inventor of a recent patent.